. 2015 Feb 9;6(5):2782–2789. doi: 10.1039/c4sc03739a

Table 1. In vitro and in situ inhibition of recombinant human GH29 α-l-fucosidase, given as half-maximal inhibitory concentration (IC₅₀) ^a .

	In vitro IC₅₀	In situ IC₅₀
Aziridine
1 (JJB256)	6.9 ± 0.8	28.9 ± 4.4
2 (JJB244)	8.7 ± 1.2	157.8 ± 22
3 (JJB243)	7.2 ± 1.1	25 512 ± 2278
4	371.6 ± 21.2	515.4 ± 72.9
5	46.8 ± 3.4	77.9 ± 9.1
23	8.7 ± 1.1	65.4 ± 7.5

Iminosugars
6	3979 ± 257	ND
7–13	>100 000	ND

^aValues are given in nanomolar. ND: not determined. It should be noted that IC₅₀ values on competitive inhibitors do not compare well to those obtained for mechanism-based inhibitors. The values given above allow for a comparison of inhibitory potency within the two classes of compounds studied.

Table 1. In vitro and in situ inhibition of recombinant human GH29 α-l-fucosidase, given as half-maximal inhibitory concentration (IC50) a .

Table 1. In vitro and in situ inhibition of recombinant human GH29 α-l-fucosidase, given as half-maximal inhibitory concentration (IC₅₀) ^a .